PK MED

PK MED is a private French biotech company developing custom-designed, injectable, biodegradable micro-implants for localized drug delivery and tissue-targeted therapies. The company was founded in 2019 and focuses on rheumatology and bone marrow transplantation support, using biomaterials and drug delivery engineering to create controlled-release local treatments. Its disclosed pipeline includes PKM-01 for gout flares, PKM-011 for osteoarthritis, and PKM-02 for improving cell homing in hemoglobinopathies and bone marrow transplantation settings. PK MED has stated that PKM-01 received FDA clearance in February 2024 to start a Phase 2 clinical program, while the broader portfolio remains early stage. The company appears to be venture-backed and grant-supported, with disclosed support from Truffle Capital and Bpifrance.